

INPLASY

A Systematic Review of Therapies in Hidradenitis Suppurativa to Inform Guideline Development

INPLASY202430041

doi: 10.37766/inplasy2024.3.0041

Received: 11 March 2024

Published: 11 March 2024

Frew, J¹.

Corresponding author:

John Frew

john.frew@unsw.edu.au

Author Affiliation:

UNSW.

ADMINISTRATIVE INFORMATION

Support - Nil.

Review Stage at time of this submission - The review has not yet started.

Conflicts of interest - None declared.

INPLASY registration number: INPLASY202430041

Amendments - This protocol was registered with the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY) on 11 March 2024 and was last updated on 11 March 2024.

INTRODUCTION

Review question / Objective To Systematically review the efficacy of interventions in Hidradenitis Suppurativa, in order to inform guideline development in Australia.

Rationale Hidradenitis Suppurativa is a chronic inflammatory skin disease with a rapidly growing armamentarium of therapies. Revision of existing guidelines in Australia is necessary in order to provide the safest and most effective therapies for patients, and to guide clinicians choice of therapeutics.

Hence this systematic review will be undertaken to collect data regarding efficacy of various therapies in this disease, in order to inform round table discussion regarding guideline development.

Condition being studied Hidradenitis Suppurativa- a chronic inflammatory skin disease impacting an estimated 1% of the population.

METHODS

Search strategy Eligibility criteria for this review would include randomized controlled trials, uncontrolled clinical trials, cohort studies, case-control studies and other observational studies with no restrictions of patient age, sex, ethnicity or language of publication.

Databases would include Pubmed, Medline, and Web of science up until February 29 2024.

Search terms would include "Hidradenitis Suppurativa"; "Acne Inversa" "Therapy" "Treatment" "Biologics" "Surgery" "Laser" "Intervention".

Participant or population No restrictions of patient age, sex, ethnicity or language of publication.

Intervention All therapeutic Interventions.

Comparator Nil.

Study designs to be included Randomized controlled trials, uncontrolled clinical trials, cohort studies, case-control studies and other observational studies.

Eligibility criteria Nil.

Information sources Pubmed, Medline, Web of Science up until February 29 2024.

Main outcome(s) Efficacy as defined by HiSCR-50/HiSCR-75 (Hidradenitis Suppurativa Clinical Response) or the IHS4-55 (International Hidradenitis Suppurativa Severity Score).

Additional outcome(s) Nil.

Data management Data collection was performed independently by 2 authors with any disagreements regarding inclusion of citations being referred to a third author for mediation.

Quality assessment / Risk of bias analysis Quality assessment will be performed by the Newcastle scale for bias.

Strategy of data synthesis Data will be presented descriptively and presented to a round table discussion in the development of treatment guidelines.

Subgroup analysis Nil.

Sensitivity analysis Nil.

Language restriction Nil.

Country(ies) involved Australia.

Other relevant information Nil.

Keywords Hidradenitis Suppurativa; Acne Inversa; Treatment; Therapy; Intervention.

Dissemination plans Publication in an Australian journal and dissemination to clinicians.

Contributions of each author

Author 1 - John Frew.

Email: john.frew@unsw.edu.au